Cargando…
HLA genotyping in the international Type 1 Diabetes Genetics Consortium
Background Although human leukocyte antigen (HLA) DQ and DR loci appear to confer the strongest genetic risk for type 1 diabetes, more detailed information is required for other loci within the HLA region to understand causality and stratify additional risk factors. The Type 1 Diabetes Genetics Cons...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917849/ https://www.ncbi.nlm.nih.gov/pubmed/20595243 http://dx.doi.org/10.1177/1740774510373494 |
_version_ | 1782185090140340224 |
---|---|
author | Mychaleckyj, Josyf C Noble, Janelle A Moonsamy, Priscilla V Carlson, Joyce A Varney, Michael D Post, Jeff Helmberg, Wolfgang Pierce, June J Bonella, Persia Fear, Anna Lisa Lavant, Eva Louey, Anthony Boyle, Sean Lane, Julie A Sali, Paul Kim, Samuel Rappner, Rebecca Williams, Dustin T Perdue, Letitia H Reboussin, David M Tait, Brian D Akolkar, Beena Hilner, Joan E Steffes, Michael W Erlich, Henry A |
author_facet | Mychaleckyj, Josyf C Noble, Janelle A Moonsamy, Priscilla V Carlson, Joyce A Varney, Michael D Post, Jeff Helmberg, Wolfgang Pierce, June J Bonella, Persia Fear, Anna Lisa Lavant, Eva Louey, Anthony Boyle, Sean Lane, Julie A Sali, Paul Kim, Samuel Rappner, Rebecca Williams, Dustin T Perdue, Letitia H Reboussin, David M Tait, Brian D Akolkar, Beena Hilner, Joan E Steffes, Michael W Erlich, Henry A |
author_sort | Mychaleckyj, Josyf C |
collection | PubMed |
description | Background Although human leukocyte antigen (HLA) DQ and DR loci appear to confer the strongest genetic risk for type 1 diabetes, more detailed information is required for other loci within the HLA region to understand causality and stratify additional risk factors. The Type 1 Diabetes Genetics Consortium (T1DGC) study design included high-resolution genotyping of HLA-A, B, C, DRB1, DQ, and DP loci in all affected sibling pair and trio families, and cases and controls, recruited from four networks worldwide, for analysis with clinical phenotypes and immunological markers. Purpose In this article, we present the operational strategy of training, classification, reporting, and quality control of HLA genotyping in four laboratories on three continents over nearly 5 years. Methods Methods to standardize HLA genotyping at eight loci included: central training and initial certification testing; the use of uniform reagents, protocols, instrumentation, and software versions; an automated data transfer; and the use of standardized nomenclature and allele databases. We implemented a rigorous and consistent quality control process, reinforced by repeated workshops, yearly meetings, and telephone conferences. Results A total of 15,246 samples have been HLA genotyped at eight loci to four-digit resolution; an additional 6797 samples have been HLA genotyped at two loci. The genotyping repeat rate decreased significantly over time, with an estimated unresolved Mendelian inconsistency rate of 0.21%. Annual quality control exercises tested 2192 genotypes (4384 alleles) and achieved 99.82% intra-laboratory and 99.68% inter-laboratory concordances. Limitations The chosen genotyping platform was unable to distinguish many allele combinations, which would require further multiple stepwise testing to resolve. For these combinations, a standard allele assignment was agreed upon, allowing further analysis if required. Conclusions High-resolution HLA genotyping can be performed in multiple laboratories using standard equipment, reagents, protocols, software, and communication to produce consistent and reproducible data with minimal systematic error. Many of the strategies used in this study are generally applicable to other large multi-center studies. |
format | Text |
id | pubmed-2917849 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-29178492010-08-13 HLA genotyping in the international Type 1 Diabetes Genetics Consortium Mychaleckyj, Josyf C Noble, Janelle A Moonsamy, Priscilla V Carlson, Joyce A Varney, Michael D Post, Jeff Helmberg, Wolfgang Pierce, June J Bonella, Persia Fear, Anna Lisa Lavant, Eva Louey, Anthony Boyle, Sean Lane, Julie A Sali, Paul Kim, Samuel Rappner, Rebecca Williams, Dustin T Perdue, Letitia H Reboussin, David M Tait, Brian D Akolkar, Beena Hilner, Joan E Steffes, Michael W Erlich, Henry A Clin Trials Articles Background Although human leukocyte antigen (HLA) DQ and DR loci appear to confer the strongest genetic risk for type 1 diabetes, more detailed information is required for other loci within the HLA region to understand causality and stratify additional risk factors. The Type 1 Diabetes Genetics Consortium (T1DGC) study design included high-resolution genotyping of HLA-A, B, C, DRB1, DQ, and DP loci in all affected sibling pair and trio families, and cases and controls, recruited from four networks worldwide, for analysis with clinical phenotypes and immunological markers. Purpose In this article, we present the operational strategy of training, classification, reporting, and quality control of HLA genotyping in four laboratories on three continents over nearly 5 years. Methods Methods to standardize HLA genotyping at eight loci included: central training and initial certification testing; the use of uniform reagents, protocols, instrumentation, and software versions; an automated data transfer; and the use of standardized nomenclature and allele databases. We implemented a rigorous and consistent quality control process, reinforced by repeated workshops, yearly meetings, and telephone conferences. Results A total of 15,246 samples have been HLA genotyped at eight loci to four-digit resolution; an additional 6797 samples have been HLA genotyped at two loci. The genotyping repeat rate decreased significantly over time, with an estimated unresolved Mendelian inconsistency rate of 0.21%. Annual quality control exercises tested 2192 genotypes (4384 alleles) and achieved 99.82% intra-laboratory and 99.68% inter-laboratory concordances. Limitations The chosen genotyping platform was unable to distinguish many allele combinations, which would require further multiple stepwise testing to resolve. For these combinations, a standard allele assignment was agreed upon, allowing further analysis if required. Conclusions High-resolution HLA genotyping can be performed in multiple laboratories using standard equipment, reagents, protocols, software, and communication to produce consistent and reproducible data with minimal systematic error. Many of the strategies used in this study are generally applicable to other large multi-center studies. SAGE Publications 2010-08 /pmc/articles/PMC2917849/ /pubmed/20595243 http://dx.doi.org/10.1177/1740774510373494 Text en © The Author(s), 2010 http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Articles Mychaleckyj, Josyf C Noble, Janelle A Moonsamy, Priscilla V Carlson, Joyce A Varney, Michael D Post, Jeff Helmberg, Wolfgang Pierce, June J Bonella, Persia Fear, Anna Lisa Lavant, Eva Louey, Anthony Boyle, Sean Lane, Julie A Sali, Paul Kim, Samuel Rappner, Rebecca Williams, Dustin T Perdue, Letitia H Reboussin, David M Tait, Brian D Akolkar, Beena Hilner, Joan E Steffes, Michael W Erlich, Henry A HLA genotyping in the international Type 1 Diabetes Genetics Consortium |
title | HLA genotyping in the international Type 1 Diabetes Genetics
Consortium |
title_full | HLA genotyping in the international Type 1 Diabetes Genetics
Consortium |
title_fullStr | HLA genotyping in the international Type 1 Diabetes Genetics
Consortium |
title_full_unstemmed | HLA genotyping in the international Type 1 Diabetes Genetics
Consortium |
title_short | HLA genotyping in the international Type 1 Diabetes Genetics
Consortium |
title_sort | hla genotyping in the international type 1 diabetes genetics
consortium |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917849/ https://www.ncbi.nlm.nih.gov/pubmed/20595243 http://dx.doi.org/10.1177/1740774510373494 |
work_keys_str_mv | AT mychaleckyjjosyfc hlagenotypingintheinternationaltype1diabetesgeneticsconsortium AT noblejanellea hlagenotypingintheinternationaltype1diabetesgeneticsconsortium AT moonsamypriscillav hlagenotypingintheinternationaltype1diabetesgeneticsconsortium AT carlsonjoycea hlagenotypingintheinternationaltype1diabetesgeneticsconsortium AT varneymichaeld hlagenotypingintheinternationaltype1diabetesgeneticsconsortium AT postjeff hlagenotypingintheinternationaltype1diabetesgeneticsconsortium AT helmbergwolfgang hlagenotypingintheinternationaltype1diabetesgeneticsconsortium AT piercejunej hlagenotypingintheinternationaltype1diabetesgeneticsconsortium AT bonellapersia hlagenotypingintheinternationaltype1diabetesgeneticsconsortium AT fearannalisa hlagenotypingintheinternationaltype1diabetesgeneticsconsortium AT lavanteva hlagenotypingintheinternationaltype1diabetesgeneticsconsortium AT loueyanthony hlagenotypingintheinternationaltype1diabetesgeneticsconsortium AT boylesean hlagenotypingintheinternationaltype1diabetesgeneticsconsortium AT lanejuliea hlagenotypingintheinternationaltype1diabetesgeneticsconsortium AT salipaul hlagenotypingintheinternationaltype1diabetesgeneticsconsortium AT kimsamuel hlagenotypingintheinternationaltype1diabetesgeneticsconsortium AT rappnerrebecca hlagenotypingintheinternationaltype1diabetesgeneticsconsortium AT williamsdustint hlagenotypingintheinternationaltype1diabetesgeneticsconsortium AT perdueletitiah hlagenotypingintheinternationaltype1diabetesgeneticsconsortium AT reboussindavidm hlagenotypingintheinternationaltype1diabetesgeneticsconsortium AT taitbriand hlagenotypingintheinternationaltype1diabetesgeneticsconsortium AT akolkarbeena hlagenotypingintheinternationaltype1diabetesgeneticsconsortium AT hilnerjoane hlagenotypingintheinternationaltype1diabetesgeneticsconsortium AT steffesmichaelw hlagenotypingintheinternationaltype1diabetesgeneticsconsortium AT erlichhenrya hlagenotypingintheinternationaltype1diabetesgeneticsconsortium AT hlagenotypingintheinternationaltype1diabetesgeneticsconsortium |